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oTATE-OF-THE-ART PAPER957Cardiac Computed Tomographic Angiographyames K. Min, Leslee J. Shaw, Daniel S. Berman
ince the introduction of 64-detector row cardiac computed tomographic angiography
CCTA), there has been considerable debate as to where CCTA fits into the algorithm for
ndividuals with suspected coronary artery disease (CAD). Min and colleagues describe the
atest available published evidence supporting the potential clinical and cost efficiency of
CTA, drawing attention to not only the significance but also the limitations of these
tudies. For instance, the studies showing high accuracy compared with conventional
ngiography are usually performed in subjects who had already been referred for conventional
ngiography and, therefore, have a high pre-test probability of CAD. Evaluation of acute
hest pain studies have been relatively small, single-center studies. The goal of this paper is to
ocus discussion on what future studies are both necessary and feasible for properly
etermining the role of CCTA in patients with suspected CAD.VIEWPOINT AND COMMENTARY EWS FROM THE NHLBI
eterogeneity in Cardiometabolic Risk in
Asian Americans Provides Opportunities for Research966. M. Venkat Narayan, Larissa Aviles-Santa, Reena Oza-Frank, Mona Pandey, J. David Curb,
arguerite McNeely, Maria Rosario G. Araneta, Latha Palaniappan, Swapnil Rajpathak,
lizabeth Barrett-Connor, for the Cardiovascular Disease in Asian and Pacific Islander Populations
HLBI Working Group
974iriam Jacob, Leslie Cho
here is considerable geographical, ethnic, cultural, and genetic diversity within the Asian and
acific Islander population (Asian Americans) in the U.S. Limited data suggest striking
ifferences in the risk of cardiovascular disease (CVD), obesity, type 2 diabetes, and other
VD risk factors across the Asian-American population. Varied durations of residence
n the U.S. allow for studies to investigate the interplay between ethnicity and
nvironmental exposures. These populations may offer the opportunity to further
nderstand the link between CVD, type 2 diabetes, body size, visceral adiposity, and
nsulin resistance. In an accompanying commentary, Jacob and Cho provide details
n how this research can best be accomplished.(continued on page A-25)
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976lmesartan Reduces Progression of Coronary Atherosclerosis
Independent of Blood Pressure Loweringtsushi Hirohata, Keizo Yamamoto, Toru Miyoshi, Kunihiko Hatanaka, Satoshi Hirohata,
itoshi Yamawaki, Issei Komatsubara, Masaaki Murakami, Eiki Hirose, Shinji Sato, Keisuke Ohkawa,
akoto Ishizawa, Hirosuke Yamaji, Hiroshi Kawamura, Shozo Kusachi, Takashi Murakami,
azuyoshi Hina, Tohru Ohe
his study used intravascular ultrasound (IVUS) to determine if the angiotensin-II receptor-
locking agent olmesartan slows coronary atheroma progression. Almost 250 subjects
ndergoing percutaneous coronary intervention had IVUS performed on a nonculprit lesion
nd were then randomized to olmesartan or to other blood pressure–lowering medications,
ith repeat IVUS 14 months later. Patient characteristics and blood pressure control were
dentical between the 2 groups. However, follow-up IVUS showed significantly decreased
otal atheroma volume (TAV) and percent change in percent atheroma volume (PCPAV) in
he olmesartan group (5.4% vs. 0.6% for TAV and 3.1% vs. 0.7% for PCPAV). These
esults suggest that olmesartan slows coronary atheroma progression independent of its effect
n blood pressure.ditorial Comment: Steven P. Marso, p. 983ISEASES OF THE AORTA
986eta-Analysis of Endovascular Versus Open
Surgical Repair for Descending Thoracic Aortic Diseaseavy Cheng, Janet Martin, Hani Shennib, Joel Dunning, Claudio Muneretto, Stephan Schueler,
udwig Von Segesser, Paul Sergeant, Marko Turina
he efficacy of thoracic endovascular aortic repair (TEVAR) compared with open surgery for
escending thoracic aortic disease remains unclear. Cheng and colleagues combined data from
omparative studies of TEVAR versus open repair through meta-analysis and meta-
egression. Forty-two nonrandomized studies involving almost 6,000 subjects were
ncluded. Registry data suggested overall perioperative complications were reduced
ith TEVAR. In comparative studies, all-cause mortality at 30 days (odds ratio
OR]: 0.44) and paraplegia (OR: 0.42) were reduced with TEVAR. There was no
ignificant difference in stroke, myocardial infarction, aortic reintervention, and
ortality beyond 1 year. The data from nonrandomized studies suggest that TEVAR
ay reduce early death, paraplegia, and several other complications compared with
pen surgery, although long-term data is sparse.(continued on page A-27)
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ETATINS AND ENDOTHELIAL DYSFUNCTION
1002osuvastatin Limits Negative Effects of
Ischemia Reperfusion on Endothelial Functionndrew Liuni, Mary Clare Luca, Tommaso Gori, John D. Parker
iuni and colleagues sought to determine if single-dose rosuvastatin would abrogate ischemia
nd reperfusion (IR)-induced endothelial dysfunction in humans and whether this effect is
yclooxygenase-2 (COX-2)-dependent. Volunteers were randomized to a single dose of oral
osuvastatin (40 mg) or placebo. The next day, endothelium-dependent flow-mediated
ilation (FMD) was measured before and after IR (15 min of upper arm ischemia followed
y 15 min of reperfusion). IR significantly blunted FMD in the placebo group, but
osuvastatin prevented this impairment. Pre-treatment with celecoxib completely abolished
osuvastatin’s protective effect. These findings help to understand the clinical benefits of
tatins and the potential cardiac risk of COX-2 inhibition.EART RHYTHM DISORDERS
1007A Ablation May Be Necessary When
AF CL Does Not Change During Ablationélèze Hocini, Isabelle Nault, Matthew Wright, George Veenhuyzen, Sanjiv M. Narayan, Pierre Jaïs,
ang-Teng Lim, Sébastien Knecht, Seiichiro Matsuo, Andrei Forclaz, Shinsuke Miyazaki, Amir Jadidi,
ark D. O’Neill, Frédéric Sacher, Jacques Clémenty, Michel Haïssaguerre
ocini and colleagues investigated if additional ablation in the right atrium (RA) would improve
he success of atrial fibrillation (AF) ablation procedures, and what factors would predict who was
ikely to require RA ablation. AF cycle length (CL) was monitored in both atria during stepwise
blation with a procedural end point of AF termination. Two distinct patterns of AF CL change
ere found in left atrial (LA) ablation. In 70% of patients, there was a parallel increase of AF CL
n LA and RA culminating in AF termination. In 19% of patients, RA AF CL did not prolong;
hese patients had a longer AF history and larger RA diameter. For the patients in whom RA
blation terminated AF, clinical success was good, but further studies are needed to elucidate the
omplex interplay between LA and RA sources for AF.ARDIAC IMAGING1017CTA Independently Predicts Long-Term Mortalityenjamin J. W. Chow, George A. Wells, Li Chen, Yeung Yam, Paul Galiwango, Arun Abraham,
ej Sheth, Carole Dennie, Rob S. Beanlands, Terrence D. Ruddy
how and colleagues sought to determine the prognostic value of coronary artery disease
CAD) severity and location measured with coronary computed tomographic angiography
CTA). Over 2,000 patients who had not been previously revascularized underwent clinically-
riven CTA and were followed for a mean of 16 months. Multivariate analysis showed that
AD severity (hazard ratio [HR]: 3.02) was a predictor of major adverse cardiovascular
vents, and that left ventricular ejection fraction (LVEF) (HR: 1.47) had incremental value
ver CAD severity. Using CTA, CAD severity, LVEF, and total plaque score appear to have
rognostic and incremental value over routine clinical predictors. CTA appears to be a
romising noninvasive modality with prognostic value.ditorial Comment: Daniel B. Mark, David F. Kong, p. 1029
(continued on page A-29)
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EASCULAR DISEASE
1032atio of Carotid to Brachial PP
Strongly Predicts CV and All-Cause Mortalitythanase Benetos, Frédérique Thomas, Laure Joly, Jacques Blacher, Bruno Pannier, Carlos Labat,
aolo Salvi, Harold Smulyan, Michel E. Safar
rachial and carotid pulse pressure (PP) are independent predictors of cardiovascular (CV)
isk, but measuring carotid PP is complicated. PP amplification, calculated by the
arotid/brachial (C/B) ratio, may be a better marker of CV risk. Benetos and colleagues used
cohort of 834 subjects who had brachial and carotid PP measured with pulse wave analysis
o create a nomogram to calculate carotid PP in a larger cohort of over 120,000 subjects. In
he large cohort, both brachial and carotid PP were associated with both CV and all-cause
ortality. The C/B ratio was slightly better, especially for CV mortality. While brachial PP,
alculated carotid PP, and C/B PP amplification all predict CV mortality, the C/B ratio is
ess dependent on blood pressure calibration and thus may be more useful in large population
tudies.
ditorial Comment: Theodore G. Papaioannou, Athanase D. Protogerou,
hristodoulos Stefanadis, p. 1038NTERVENTION IN CONGENITAL HEART DISEASE1041Long-Term Risk of PR Following Balloon Valvuloplasty for Pulmonary Stenosisavid M. Harrild, Andrew J. Powell, Trang X. Trang, Tal Geva, James E. Lock, Jonathan Rhodes,
off B. McElhinney
n this study, Harrild and colleagues evaluated patients previously treated for uncomplicated
alvar pulmonary stenosis with percutaneous balloon dilation (BD). Forty-one patients
nderwent cardiac magnetic resonance (CMR) imaging and treadmill testing a median 13
ears after BD. A larger balloon to annulus ratio and younger age at intervention were
ssociated with a higher pulmonary regurgitation (PR) fraction. Patients with PR fraction
15% had significantly lower peak oxygen consumption. These results help to understand the
ptimal balloon sizing for, and long-term outcomes from, pulmonic balloon valvuloplasty.ditorial Comment: Larry A. Latson, p. 1048
